XML 26 R3.htm IDEA: XBRL DOCUMENT v3.8.0.1
Consolidated Statements of Operations - CAD ($)
$ in Thousands
 12 Months Ended
Mar. 31, 2018
Mar. 31, 2017
Income Statement [Abstract]    
Revenue $ 77,948 $ 39,895
Inventory production costs expensed to cost of sales 37,790 15,293
Gross margin before the undernoted 40,158 24,602
Fair value changes in biological assets included in inventory sold and other inventory charges 66,268 34,978
Unrealized gain on changes in fair value of biological assets (100,302) (49,090)
Gross margin 74,192 38,714
Sales and marketing 38,203 12,960
Research and development 1,453 810
General and administration 43,819 16,858
Acquisition-related costs 3,406 7,369
Share-based compensation expense 29,631 8,046
Share-based compensation expense related to acquisition milestones 19,475 690
Depreciation and amortization 20,486 6,064
Operating expenses 156,473 52,797
Loss from operations (82,281) (14,083)
Share of loss on equity investments (1,473) (50)
Other income, net 31,213 3,858
Other income 29,740 3,808
Loss before income taxes (52,541) (10,275)
Income tax (expense) recovery (1,593) 2,703
Net loss (54,134) (7,572)
Net income (loss) attributable to:    
Canopy Growth Corporation (70,353) (7,521)
Non-controlling interests 16,219 (51)
Net loss $ (54,134) $ (7,572)
Earnings per share, basic and diluted    
Net loss per share: $ (0.40) $ (0.06)
Weighted average number of outstanding common shares: 177,301,767 118,989,713